

Disclaimer: This document is an English translation of the original document in Japanese and has been prepared solely for reference purposes. In the event of any discrepancy between this English translation and the original in Japanese, the original shall prevail in all respects.



October 28, 2022

To whom it may concern:

Company name	KISSEI PHARMACEUTICAL CO., LTD.
Representative	Mutsuo Kanzawa, Chairman and CEO (Stock code 4547; Prime Market, Tokyo Stock Exchange)
Contact	Takahide Kitahara, Managing Director, Department Manager of Corporate Finance and Management Department (Telephone +81-263-25-9081)

Notice Concerning Revisions to Financial Results Forecast

In light of the recent trends in financial results and other factors, KISSEI PHARMACEUTICAL CO., LTD. (the “Company”) announces that it has revised the financial results forecast announced on May 10, 2022 as follows.

● Revisions to the Financial Results Forecast

Revisions to the Consolidated Financial Results Forecast Figures for the Six Months Ended September 30, 2022 (April 1, 2022 – September 30, 2022)

	Net sales	Operating profit	Ordinary profit	Profit attributable to owners of parent	Basic earnings per share
Previously announced forecast (A)	Million yen 31,000	Million yen (1,300)	Million yen (500)	Million yen 3,000	Yen 65.05
Revised forecast (B)	32,800	(600)	300	3,300	71.56
Change (B – A)	1,800	700	800	300	
Change rate (%)	5.8	-	-	10.0	
(Reference) Results for the corresponding six months of the previous fiscal year (Six months ended September 30, 2021)	32,388	270	1,281	5,666	122.87

Reasons for the Revision

Net sales for the six months ended September 30, 2022 are expected to exceed the initial forecast due in part to the growth of domestic pharmaceuticals in the Pharmaceutical Business. Selling, general and administrative expenses are expected to increase compared to the initial forecast centering on R&D expenses such as taking over overseas clinical trials in preparation for the termination of the license agreement with ObsEva SA (Switzerland), the overseas licensee for linzagolix, a treatment for uterine fibroids and endometriosis. However, operating profit, ordinary profit, and profit attributable to owners of parent for the six months ended September 30, 2022 are expected to exceed the initial forecast due to increased net sales and an improvement in the cost of sales ratio, etc.

The financial results forecast for the full year is scheduled to be announced with the publication of the consolidated financial results for the six months ended September 30, 2022 (scheduled for November 8, 2022).

(Note) The above forecasts are based on information available to the Company as of the date of publication of this document and certain assumptions as of the date of publication of this document on uncertainties that may have an impact on future financial results. Actual results may differ greatly from these forecasts due to a variety of factors in the future.